A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Abstract Text:

Howard A Fine,Lyndon Kim,Paul S Albert,J Paul Duic,Hilary Ma,Wei Zhang,Tanyifor Tohnya,William D Figg,Cheryl Royce,Howard A Fine,Lyndon Kim,Paul S Albert,J Paul Duic,Hilary Ma,Wei Zhang,Tanyifor Tohnya,William D Figg,Cheryl Royce,

PURPOSE: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. EXPERIMENTAL DESIGN: A phase I interpatient dose escalation trial of lenalidomide in patients with recurrent primary central nervous system tumors was conducted. RESULTS: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m(2), with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months. CONCLUSION: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m(2). Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Publishing Authors By Initials

HA Fine,L Kim,PS Albert,JP Duic,H Ma,W Zhang,T Tohnya,WD Figg,C Royce,HA Fine,L Kim,PS Albert,JP Duic,H Ma,W Zhang,T Tohnya,WD Figg,C Royce,

For similar organic chemicals: carboxylic acids: acids, carbocyclic: phthalic acids: phthalimides: thalidomide research abstracts see: organic chemicals: carboxylic acids: acids, carbocyclic: phthalic acids: phthalimides: thalidomide research

PUBMED ID PMID:

MEDLINE DATE:

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 7101-6

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 1

MONTH: Dec

YEAR: 2007

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Keywords Mesh Terms:

KEYWORDS: Thalidomide

MESH TERMS: pharmacokinetics

Chemical & Substance for Abstract: A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Information

Substance Name: Thalidomide

Registry Number: 50-35-1

Grant and Affiliation Information for A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

AFFILIATION: Neuro-Oncology Branch and Medical Oncology Branch, National Cancer Institute, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892, USA. hfine@mail.nih.gov

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors Related Publications

• A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
• Breast disease: benign and malignant.
• Cortical neurons with collateral projections to both the caudate nucleus and the centromedian-parafascicular thalamic complex: a fluorescent retrograde double labeling study in the cat.
• Cost-effectiveness of alternative strategies for tuberculosis screening before kindergarten entry.
• Effect of changes in the pH and carbon dioxide evolution rate on the measured respiratory quotient of fermentations.
• Feeding premature infants; recent modifications in the in-dwelling nasogastric tube method.
• Fundamental-mode laser-beam propagation in optically inhomogeneous electrochemical media with chemical species concentration gradients.
• Hypertension in childhood; treatment of acute nephritis with a derivative of veratrum viride.